Study of the Pathogenicity and Humoral Immune Response Induced by BK Virus in Lung Transplant Recipients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-01-31

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

BK virus (BKV) is a ubiquitous virus that infects more than 80% of the population. In case of immunosuppression, BKV can replicate and induce nephropathies in renal transplant recipients or haemorrhagic cystitis in bone marrow transplant recipients. The disruption of the balance between BKV replication and immune control is considered the key element in the development of these pathologies. During lung transplantation, patients undergo intense immunosuppression that favors the reactivation of persistent viruses such as EBV, CMV and probably BKV. Although the data on EBV and CMV reactivation are very clear and allow optimal management, the prevalence of BKV replication and its clinical impact in lung transplant recipients remains unknown at this time.

The aim of this study is to know the incidence and clinical impact of BKV replication in lung transplant recipients. Moreover, the results will help to better understand the interaction between the virus and his host, with a focus on the humoral and cellular immune response against BKV. The results could possibly enable to define predictive markers of BKV replication and of its evolution.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anti-BK Virus Immune Response and Kidney Transplantation

NCT01109186

Kidney Transplantation

COMPLETED

Prediction of BK Virus Reactivation in Kidney Transplant Recipient

NCT06219616

Kidney Transplant Infection BK Virus Infection BK Virus Nephropathy

COMPLETED NA

Intravenous Immunoglobulins for Prevention of BKV Infection in Kidney Transplant Recipients According to BKV Genotype-specific Neutralizing Antibody Titers at the Day of Transplantation.

NCT04222023

Kidney Transplantation

COMPLETED PHASE4

New Therapeutic Approach Against BK Virus Infection Based on Monoclonal Antibodies

NCT05264259

BK Virus Infection

RECRUITING

Study of the Serotype and Genotype of BK Virus in Kidney Transplant Recipients and Their Donors to Identify Individuals at Risk of Nephropathy

NCT07347769

Nephropathy Opportunistic Viral Infection Polyoma Virus Nephropathy +6 more

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal-urinary Impairment Graft Rejection Infection Episodes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transplant patients

Study the specific immunity against Polyomavirus

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Lung transplant recipients in Strasbourg University Hospital between 30 June 2018 and 31 December 2022
* Male or female patients, age over 18 years
* Patient having provided informed written consent to take part in the study
* Patient affiliated to Social Security

Exclusion Criteria

* Patient deprived of liberty, by judicial or administrative decision
* Patient under legal guardianship
* Impossibility to give complete information about this study to the patient

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No